IBRN vs PSIL: Holdings Overlap & Returns
Over the year to Nov 13, 2026, IBRN returned +19.8% to PSIL's +18.6%; 11% of their weight is in the same names.
- Return gap
- +1.2 pts1 year to Nov 13, 2026: IBRN ahead, total return
- Fee gap
- 0.53 ptsA year: IBRN 0.47%, PSIL 1.00%, per filings dated Nov 21, 2025 and Oct 28, 2026
- Overlap
- 11%Share of the two books held in common, holdings dated Nov 12, 2026 and Jun 30, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
IBRN +19.8%, PSIL +18.6%: IBRN +1.2 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Cost to trade
Hypothetical. A $10,000 order in IBRN costs about $16.00 one way and $32.00 in and out, at a median spread of 0.32%. The 0.32% spread is IBRN’s 30-day median, from iShares (fund page).
Fees over time
Hypothetical. $10,000 in PSIL for 10 years at 1.00% a year costs about $1,620 in fees and lost growth; IBRN at 0.47% would cost $778. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
5% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.
8% of PSIL's weight is in S&P 500 companies and 92% is outside the index. Holdings as of Jun 30, 2026.
Key numbers
IBRN costs 0.53 points a year less; their one-year returns differ by 1.2 points; PSIL is 4.9 times larger.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +19.8% | +18.6% |
|---|---|---|
| Below its all-time high | 15.9%, high on Aug 19, 2026 | 78.3%, high on Sep 22, 2021 |
| What it tracks | Therapeutics and medical devices | Therapeutics and medical devices |
| Expense ratio | 0.47% | 1.00% |
| Net assets, as of Nov 12, 2026 | $8.6m | $42m |
| Holdings in common | 11% |
The numbers behind it
Net assets on Nov 12, 2026: $8.6m for iShares Neuroscience and Healthcare ETF and $42m for AdvisorShares Psychedelics ETF.
Holdings in common uses holdings dated Jun 30, 2026 and Nov 12, 2026.
What they share
By the books each fund has filed, IBRN and PSIL hold 11% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 12, 2026.
half
11% in common
Held in common
Show all 5 holdings
| NEUROCRINE BIOSCIENCES | 5.09% | 4.38% |
| Alkermes Public Limited Company | 4.75% | 4.30% |
| ALTO NEUROSCIENCE | 1.60% | 4.20% |
| BRIGHT MINDS BIOSCIENCES | 0.27% | 3.83% |
| SUPERNUS | 0.00% | 2.89% |
Only in IBRN
Show all 8 holdings
| BIOGEN | 5.33% |
| EDGEWISE THERAPEUTICS | 4.96% |
| ARGENX SE ADR | 4.43% |
| PRAXIS PRECISION MEDICINES | 4.30% |
| PTC THERAPEUTICS | 4.29% |
| AXOGEN | 4.28% |
| DIANTHUS THERAPEUTICS | 3.98% |
| SK BIOPHARMACEUTICALS LTD | 3.80% |
Only in PSIL
Show all 8 holdings
| DEFINIUM THERAPEUTICS INC | 12.85% |
| COMPASS PATHWAYS PLC | 11.45% |
| ATAIBECKLEY INC | 10.47% |
| RELMADA THERAPEUTICS INC | 6.84% |
| NRX PHARMACEUTICALS INC | 6.07% |
| CYBIN INC | 4.36% |
| GH RESEARCH PLC | 4.31% |
| ABBVIE INC | 4.14% |
Side by side
Open the table
| Fund | iShares Neuroscience and Healthcare ETF · Holds 67 stocks in therapeutics and medical devices, 5% of its weight in S&P 500 companies | AdvisorShares Psychedelics ETF · Holds 27 stocks in therapeutics and medical devices, 8% of its weight in S&P 500 companies |
| Issuer | iShares | AdvisorShares |
| Theme | Therapeutics and medical devices | Therapeutics and medical devices |
| In the S&P 500 | 5.3% | 7.8% |
| Active share vs the S&P 500 | 100.0% | 98.4% |
| In the Nasdaq-100 | 0.0% | 0.0% |
| Holdings | 67 | 27 |
| Top ten, share of the fund | 45.2% | 69.2% |
| Expense ratio | 0.47% | 1.00% |
| Fee for the differing part | 0.47% | 1.02% |
| Total return, 1 year | +19.8% | +18.6% |
| vs its benchmark | not measured | not measured |
| Below its high | −15.9% | −78.3% |
| Net assets, as of Nov 12, 2026 | $8.6m | $42m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | −12.6% | −23.9% |
|---|---|---|
| 6 months | −1.7% | −3.7% |
| 1 year | +19.8% | +18.6% |
| 3 years | +67.5% | +62.8% |
| Since launch (Not the same days: IBRN Aug 2022 · PSIL Sep 2021) | +41.2% | −77.7% |
About IBRN
By weight, 5% of IBRN's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 45% of the fund across 67 positions, as published by its issuer for Nov 12, 2026.
More
Over the year to Nov 13, 2026 the fund returned +19.8% with distributions reinvested. It sits 15.9% below its all-time high of Aug 19, 2026.
About PSIL
By weight, 8% of PSIL's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 69% of the fund across 27 positions, as filed for Jun 30, 2026.
More
Over the year to Nov 13, 2026 the fund returned +18.6% with distributions reinvested. It sits 78.3% below its all-time high of Sep 22, 2021.
11% of the two portfolios are the same securities at the same weight.
Questions people ask
Do IBRN and PSIL hold the same stocks?
By their latest filings, 11% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, IBRN against PSIL, data as of Nov 13, 2026. https://etfiq.com/compare/themes/ibrn-vs-psil
ETFIQ. (Nov 13, 2026). IBRN against PSIL. Retrieved from https://etfiq.com/compare/themes/ibrn-vs-psil
[IBRN against PSIL (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/ibrn-vs-psil)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.